{"ticker": {"uuid": "b29c3c6e-448b-4e7c-9b6c-aaaa9347d8f6", "symbol": "OCUL", "name": "Ocular Therapeutix Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Citizens reiterates Ocular Therapeutix stock rating on Dextenza sales", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxNN1hWcmMtLUFhN1pWNmpCSjVfNHRvdlBiN0Zfa2JoeU1YTXJxdFB2eml3NlgyVkphREVEd1pJZE5yLUFVNkcyeXo0azRXc2FnQWZQTncxME5WWFJSWVQyLWh5bXU0Mms5RXFDazU5bmtpeXVFdFMxM0xQRGhwREM4akFVNVlvMkp0RVlQRmZhc3ZNWkdKR1lwa2FUZ2RjRTVQSHVaYmIyMWtYX0hfNGgxb1EtaUpNVjhVTl9SaDBzUGs4VEdwZUlKbQ?oc=5", "source_name": "Investing.com", "published_at": "2026-07-17T10:42:46+00:00", "published_display": "17 Jul 2026 10:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Nasdaq, S&P 500 Futures Lower As AI Disruption Fears Linger: Why AAPL, ZIM, OCUL, NCLH Are On Traders' Radar Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxNMWlVUlMxNmxZNFZvb3J0cWpqa3l1aW1hUDZnT2Fwc25hQ3poM29TV1BOdmFTSVVaMWtuR2ZPZGJRZjVfS0xlWVE4RjFwY3U4UnMwTmxEY082b2xlanJabDVuLWkxU1o3SDFUNVhxcmhjV1o1RThPdVFBckpBV2NRbVJsMFhTTHllTVZ1UTZscmEwenZNUlhZME1IUUE4a2lTX3NMQTZtN1Z1eXNWTm9xOWVjQ3h5UWR6d0NJcHh3Y0UwUQ?oc=5", "source_name": "Stocktwits", "published_at": "2026-07-16T14:06:06+00:00", "published_display": "16 Jul 2026 14:06", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocular Therapeutix Inc (OCUL) Institutional Confidence", "summary": "", "url": "https://news.google.com/rss/articles/CBMicEFVX3lxTE5FY1JkUFVFNEdRZUgySVRVeWUwU2lNbXhLcXJaNjRTTnhtVDFIc0Rxa3loQ1JhYkQ3Ny0yb3VGUVlpM254RHFzLWVQMEphNC1RN2YzUjZoSGVsTzlZbGNOZGt0RzRXNmZibVF3X19ubGg?oc=5", "source_name": "TradingKey", "published_at": "2026-07-14T07:00:00+00:00", "published_display": "14 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "(OCUL) Price Dynamics and Execution-Aware Positioning", "summary": "This article from Stock Traders Daily provides a detailed AI-driven analysis of Ocular Therapeutix Inc. (NASDAQ: OCUL), highlighting strong near and mid-term sentiment potentially shifting to a weak long-term outlook. It outlines specific institutional trading strategies, includi", "url": "https://news.stocktradersdaily.com/news_release/22/OCUL_Price_Dynamics_and_Execution-Aware_Positioning_071226014602_1783835162.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-12T01:41:34", "published_display": "12 Jul 2026 01:41", "sentiment": "negative", "sentiment_pct": 38, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocular Therapeutix\u2122 Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)", "summary": "Ocular Therapeutix, Inc. announced inducement grants to eleven new non-executive employees, consisting of stock options and restricted stock units. These awards, totaling 34,700 shares for options and 11,375 for RSUs, were made under Ocular\u2019s 2019 Inducement Stock Incentive Plan ", "url": "https://www.globenewswire.com/news-release/2026/07/09/3325203/0/en/ocular-therapeutix-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html", "source_name": "GlobeNewswire", "published_at": "2026-07-10T07:11:15", "published_display": "10 Jul 2026 07:11", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Does Ocular Therapeutix (OCUL) Joining Russell Value Indexes Quietly Recast Its Long\u2011Term Investor Base?", "summary": "Ocular Therapeutix (OCUL) was recently added to several Russell Value indexes, which could increase its visibility to institutional investors and improve trading volumes. While this inclusion may boost short-term liquidity, the company's long-term investment narrative remains dep", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ocul/ocular-therapeutix/news/does-ocular-therapeutix-ocul-joining-russell-value-indexes-q", "source_name": "Simply Wall Street", "published_at": "2026-07-10T05:09:42", "published_display": "10 Jul 2026 05:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocular Therapeutix (OCUL) Joins Russell Value Indexes, Is The Stock Now Too Pricey?", "summary": "Ocular Therapeutix (OCUL), recently added to Russell indexes, has seen a sharp rebound in its stock price, but remains down year-to-date. Despite being considered \"undervalued\" with a fair value of $26 based on the potential of its drug AXPAXLI, its current price-to-sales ratio i", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ocul/ocular-therapeutix/news/ocular-therapeutix-ocul-joins-russell-value-indexes-is-the-s/amp", "source_name": "Simply Wall Street", "published_at": "2026-07-08T12:09:50", "published_display": "08 Jul 2026 12:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocular Therapeutix options trading jumps to 9,894 contracts", "summary": "Trading in options for Ocular Therapeutix Inc. (NASDAQ:OCUL) surged to 9,894 contracts by 10:51 a.m. New York time, with call volume notably higher than put volume. Specifically, the July 17, 2026 $9 call option accounted for 9,807 contracts. Despite the increased options activit", "url": "https://www.investing.com/news/stock-market-news/ocular-therapeutix-options-trading-jumps-to-9894-contracts-93CH-4776966", "source_name": "Investing.com", "published_at": "2026-07-06T15:11:43", "published_display": "06 Jul 2026 15:11", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocular Therapeutix Inc Actuals & Estimates (NASDAQ:OCUL)", "summary": "Ocular Therapeutix Inc. (NASDAQ: OCUL) stock is currently priced at $10.16, showing a 6.94% increase in the past 24 hours. Analysts project a price target range of $18.00 to $34.00, indicating potential growth. The company reported earnings per share of -$0.40 last quarter, missi", "url": "https://www.tradingview.com/symbols/NASDAQ-OCUL/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-07-04T19:09:50", "published_display": "04 Jul 2026 19:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Ocular Therapeutix, Inc. \u2013 NASDAQ:OCUL", "summary": "This article provides the stock ticker (OCUL) and company name (Ocular Therapeutix, Inc.) along with a financial metric: Price to Earnings Forward. It indicates that the market is currently closed and no trades have occurred for the stock.", "url": "https://www.tradingview.com/symbols/NASDAQ-OCUL/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-04T08:11:07", "published_display": "04 Jul 2026 08:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Ocular Therapeutix, Inc. \u2013 NASDAQ:OCUL", "summary": "This article focuses on the price-to-sales forward metric for Ocular Therapeutix, Inc. (NASDAQ: OCUL). The content, provided by TradingView, lists the company's financial overview and other market data points like financials, news, and technicals. It indicates that the market for", "url": "https://www.tradingview.com/symbols/NASDAQ-OCUL/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-03T15:10:09", "published_display": "03 Jul 2026 15:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OCUL - Ocular Therapeutix Inc Revenue Breakdown", "summary": "This article provides a comprehensive financial overview of Ocular Therapeutix Inc. (OCUL), detailing its revenue breakdown, market performance, key financial ratios, and analyst recommendations. It includes data on market capitalization, income, sales, earnings per share, inside", "url": "https://finviz.com/stock?t=OCUL&ty=rv&=scroll", "source_name": "Finviz", "published_at": "2026-07-02T12:39:34", "published_display": "02 Jul 2026 12:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocular Therapeutix to present new retinal disease data at July 2026 scientific and investor conferences", "summary": "Ocular Therapeutix announced its plans to present new data on its investigational retinal drug AXPAXLI and real-world anti-VEGF treatment outcomes at various scientific and investor conferences in July 2026. These events include the OIS Retina Innovation Summit and the American S", "url": "https://pluang.com/en/news-feed/ocular-therapeutix-ikut-konferensi-ilmiah-dan-investor-juli-2026", "source_name": "Pluang", "published_at": "2026-07-01T12:11:38", "published_display": "01 Jul 2026 12:11", "sentiment": "positive", "sentiment_pct": 67, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocular Therapeutix\u2122 to Participate in July Scientific and Investor Conferences", "summary": "Ocular Therapeutix, Inc. (NASDAQ: OCUL) announced its participation in multiple scientific and investor conferences in July 2026. These events include the 9th Annual OIS Retina Innovation Summit, the American Society of Retina Specialists 44th Annual Meeting, and the HC Wainwrigh", "url": "https://www.globenewswire.com/news-release/2026/07/01/3320488/0/en/ocular-therapeutix-to-participate-in-july-scientific-and-investor-conferences.html", "source_name": "GlobeNewswire", "published_at": "2026-07-01T11:11:38", "published_display": "01 Jul 2026 11:11", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocular Therapeutix will present SOL-1 data at July retina meetings", "summary": "Ocular Therapeutix (NASDAQ: OCUL) announced its participation in multiple scientific and investor conferences in July 2026. The company will present Phase 3 SOL-1 trial results for OTX-TKI in neovascular age-related macular degeneration (nAMD) at the ASRS 44th Annual Meeting and ", "url": "https://www.stocktitan.net/news/OCUL/ocular-therapeutix-tm-to-participate-in-july-scientific-and-investor-llrsd185hy8g.html", "source_name": "Stock Titan", "published_at": "2026-07-01T11:11:38", "published_display": "01 Jul 2026 11:11", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Does Broad Russell Value Index Inclusion Reshape the Bull Case for Ocular Therapeutix (OCUL)?", "summary": "Ocular Therapeutix (OCUL) was recently added to several Russell value indices, which could increase its visibility among institutional investors and improve liquidity. While this inclusion may reshape market perception of Ocular Therapeutix's risk profile, the company's investmen", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ocul/ocular-therapeutix/news/does-broad-russell-value-index-inclusion-reshape-the-bull-ca", "source_name": "Simply Wall Street", "published_at": "2026-07-01T11:11:38", "published_display": "01 Jul 2026 11:11", "sentiment": "positive", "sentiment_pct": 67, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocular Therapeutix (OCUL) Could Be 62% Below Fair Value After Axpaxli FDA Feedback", "summary": "Ocular Therapeutix (OCUL) is in the spotlight due to positive FDA feedback on its drug Axpaxli, intended for wet age-related macular degeneration. Despite a recent share price surge, the company's year-to-date performance is down, though its three-year shareholder return remains ", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ocul/ocular-therapeutix/news/ocular-therapeutix-ocul-could-be-62-below-fair-value-after-a", "source_name": "Simply Wall Street", "published_at": "2026-06-29T03:39:43", "published_display": "29 Jun 2026 03:39", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OCUL Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides an in-depth forecast for Ocular Therapeutix, Inc. (OCUL) stock, including current price, analyst price targets, and historical performance. It details financial metrics such as EPS, revenue, net income, and EBITDA, along with frequently asked questions about", "url": "https://www.tradingview.com/symbols/NASDAQ-OCUL/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-27T00:09:08", "published_display": "27 Jun 2026 00:09", "sentiment": "positive", "sentiment_pct": 60, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocular Therapeutix Inc Actuals & Estimates (BX:0OT)", "summary": "This article provides an overview of Ocular Therapeutix Inc (BX:0OT) stock, including its current price, market capitalization, and historical performance. It also details financial actuals and estimates, analyst forecasts for future prices, and information on earnings reports, r", "url": "https://www.tradingview.com/symbols/BX-0OT/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T15:14:24", "published_display": "26 Jun 2026 15:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocular Therapeutix Inc Actuals & Estimates (FWB:0OT)", "summary": "This article provides financial actuals and estimates for Ocular Therapeutix Inc (FWB:0OT), including analyst opinions on future prices, historical stock performance, and past earnings reports. It details the company's revenue, net income, EBITDA, and employee count, confirming t", "url": "https://www.tradingview.com/symbols/FWB-0OT/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T11:09:08", "published_display": "26 Jun 2026 11:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OCUL Maintained by Chardan Capital -- Price Target Raised to $23", "summary": "Chardan Capital has reiterated its \"Buy\" rating for Ocular Therapeutix (OCUL) and raised its price target from $21.00 to $23.00, signaling optimism about the company's future. Despite this positive analyst sentiment, GuruFocus indicates that OCUL is significantly overvalued by 12", "url": "https://www.gurufocus.com/news/8931844/ocul-maintained-by-chardan-capital-price-target-raised-to-2300", "source_name": "GuruFocus", "published_at": "2026-06-25T14:39:58", "published_display": "25 Jun 2026 14:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chardan Raises Price Target on Ocular Therapeutix to $23 From $21, Keeps Buy Rating", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/chardan-raises-price-target-ocular-111221755.html", "source_name": "MT Newswires", "published_at": "2026-06-25T11:12:21+00:00", "published_display": "25 Jun 2026 11:12", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Ocular Therapeuticx, Inc. (OCUL) Stock Positioned for Growth After Positive FDA Feedback on Axpaxli?", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxQQWZ6c1hZdDRIa3FaTXUwa3I5VGp4a0FIekRTTUNiZnNQYllkc3VJXzVWSkJFMDI3Wk00WTJaLW5kWW54Wkk5SERaNk1fYk5iamliZV84VlR5dnNFNF9Oc3djSHZLMEtadUhkRlRzM3RTd2lOUURsM1Fnd3ZoTW1nelE3Y0VGdEhrOG4zcTZ5RG1OdmE5T0dnZGtfMA?oc=5", "source_name": "Market source", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "5 Best Healthcare Stocks to Buy According to Wall Street Analysts", "summary": "Ocular Therapeutix, Inc. (NASDAQ: OCUL) is highlighted as one of the best healthcare stocks, with H.C. Wainwright increasing its price target to $25 based on positive feedback from a Type C meeting with the FDA for AXPAXLI. The company plans to submit a New Drug Application for A", "url": "https://www.insidermonkey.com/blog/5-best-healthcare-stocks-to-buy-according-to-wall-street-analysts-1788076/5/", "source_name": "Insider Monkey", "published_at": "2026-06-24T19:39:00", "published_display": "24 Jun 2026 19:39", "sentiment": "positive", "sentiment_pct": 74, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocular Therapeutix (OCUL): Buy, Sell, or Hold Post Q1 Earnings?", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxQQzJaS050bXRKQ1FZdVpodlRyS0pTcG1iU0JLX2Y1dUlQSjlPUnhqZkVOYkt2YWlEQ0FsanhoZzA0Z2gtN3duWFBZVldLVThncHZyNHYtZTd6VVFPOHdwbXZZelRPM0FseFEzVUR4TmJEUHIxbXB6dm8wc0V3elIzOUZ1eU0tVFp5WDQ5SWVmRUNPaXc5dklHdEVmTlBrUQ?oc=5", "source_name": "Market source", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)", "summary": "Ocular Therapeutix announced inducement grants under Nasdaq Listing Rule 5635(c)(4). These grants are typically given to new employees as an incentive to join the company. This action reflects the company's efforts to attract and retain talent in line with Nasdaq's regulatory fra", "url": "https://www.moomoo.com/news/post/71847001/ocular-therapeutix-reports-inducement-grants-under-nasdaq-listing-rule-5635", "source_name": "Moomoo", "published_at": "2026-06-23T13:09:10", "published_display": "23 Jun 2026 13:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright raises Ocular Therapeutix price target to $25 on FDA pathway clarity", "summary": "H.C. Wainwright has increased its price target for Ocular Therapeutix (NASDAQ:OCUL) to $25 from $21, maintaining a Buy rating. This adjustment follows Ocular Therapeutix's Investor Day, where the company provided clarity on its FDA pathway for AXPAXLI, including aligning with the", "url": "https://ng.investing.com/news/stock-market-news/hc-wainwright-raises-ocular-therapeutix-price-target-to-25-on-fda-pathway-clarity-93CH-2567443", "source_name": "Investing.com Nigeria", "published_at": "2026-06-23T00:39:56", "published_display": "23 Jun 2026 00:39", "sentiment": "positive", "sentiment_pct": 75, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocular Therapeutix grants new SVP equity awards tied to hiring", "summary": "Ocular Therapeutix (NASDAQ: OCUL) has awarded inducement equity grants to Kelley Allison, its new SVP of Market Access and Health Policy, under its 2019 Inducement Stock Incentive Plan. These grants include options for 85,000 shares at an exercise price of $8.99 and 28,000 Restri", "url": "https://www.stocktitan.net/news/OCUL/ocular-therapeutix-tm-reports-inducement-grants-under-nasdaq-listing-4yx69oxb2vn0.html", "source_name": "Stock Titan", "published_at": "2026-06-22T20:11:11", "published_display": "22 Jun 2026 20:11", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stocks making big moves yesterday: Nubank, Ocular Therapeutix, Mondelez, ResMed, and Sonos", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/stocks-making-big-moves-yesterday-151728482.html", "source_name": "StockStory", "published_at": "2026-06-18T15:17:28+00:00", "published_display": "18 Jun 2026 15:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocular Therapeutix Says Axpaxli New Drug Application Submission to US FDA Planned for Q4", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/ocular-therapeutix-says-axpaxli-drug-141652961.html", "source_name": "MT Newswires", "published_at": "2026-06-17T14:16:52+00:00", "published_display": "17 Jun 2026 14:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Ocular Therapeutix (OCUL) Stock Is Up Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxQV3hTbWNKX0lKUXQyYzZDemtKY2pDVUtIQkphTy1uT3hlNVJRWEMwUDY1ZHpvNDZMV0UxZWxSckxJMExKb2t1dGdmUWlnMHpOY09wdEJpQ2pMNmdBdlJzTVhNR3RkeW1PRDFPU3ZzckVmaHpzd1Z3Rjh4MVZmdmdsODVVM3NqQkhEWG5WdnVJMzNIWjF4ZmhEZ1NB?oc=5", "source_name": "Market source", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocular Therapeutix maps AXPAXLI filing for wet AMD after FDA alignment", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxQSEVVVm5IS1ktMUltQnVCVzkzaGxvWnlKbkg0SjB2bjZCUFRlV0ZMZ1RxNEtvQmNfYjNMel9vYV9iMmtnSzA0MG1RRzFzaEJSTXU5b0RUWXpBa3dkMGVjcFJ4cWZVdXpsVkRRUkJJWVItRXNNTVdiTkdlVFZjYzN1SE5kSGVXSFBNWWVmb2NNX0NnOGVmMVZLaTEwYTVTbEVaRUR4MXU3b0pUM1FYOG1lYWlZWm96Z1Q2dWNfMWVaQ0Y?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocular Therapeutix plans wet AMD drug filing in Q4 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxObHBoS3B1OE9POUpsYW1nd2dDUXV0RjRYUDdzSGVyUFgyZmk0RmcxOHBnTnUwXzRvNUZjRmJxVXVjS0pjaFYtVVpfMjBMS3NNc1VqM1FfdGRZMUJrbkVLaEJvSXY4TjZ3emVjdk1Qem0tODJOOHNlWTRYSUZRdzJ3eFpkeS1VNmd3RVVILWg3bHJtajIzUkpra3p4UTdmX25uVWxMaS1lUFMtS3dpemxhNnFn?oc=5", "source_name": "Investing.com", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocular Therapeutix vs. Prime Medicine: Which Healthcare Stock Is a Better Buy in 2026?", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxQZllJdWRvZFgyZmg3WTR4T2I0MG16eEtUOXk1RzNTRGhpLWhLUnFMVnRZN1JrT2JtUDhJRHIxT2pGdVR6UDdNcUtIS3B3YUdGUFFNbWlqWGJHbHRXajE5N3VXdnRzekdCeFM3S2tpbVF2bjQ4SUlkTG5OMUJpWkN1VWkwT2ZRWF9JdFljQi02S2J1UHZSLXRPWUk2SDRqMEJYUUxONWJHMFBGZnppTm9mTlQ0eko0blhKVUFIR2N4eEI3dDZTQTN6LUoyczNNQmJfeXc?oc=5", "source_name": "The Motley Fool", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocular Therapeutix vs. Prime Medicine: A 2026 Analysis of Medical Innovation Stocks - News and Statistics", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxNWmVXNFFqeG1CSVJyMkJhYmV4NHV6Q3dGX2I2RTJGdWdYUkE5RlpiQUxZTEliemVKU3A4QXFLbjZxa1NmbVFKbzN3akNQS0pZcC1yeXUxVFNRdVFHVEFBcmQ1YkdLRVFubXJUQndSYXNNUll0elhlRW1uUkxXLU0tdHlTVmllZ0xZTzNTZmRLZ3lRZjlSVEFVX01uYTljVDBPaHJRWDllR0RnbDdCdzRHckxfUjFqZVhWMFE?oc=5", "source_name": "IndexBox", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What This Fund\u2019s $14 Million Ocular Therapeutix Exit Could Signal for Investors", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxQbXNhdk1DTkMyQjJYWFdPVXZWNmxMVlZWaFBVajNDNWdZTkNBeDNRaVpyckZEcXI5RXo0em9LQUJTSzN4VUtnZFFUSW5fYnBYTmJYeGozZ2x6aHFITWNhRmhpYlFkS0ppaEZJUm9VbEVhZ2F4TEVicTlOdE02YmE2NlhjOG1DYUNUU0p6OU1XZnVmcmcycm5zQ05aMk1pTnBI?oc=5", "source_name": "Market source", "published_at": "2026-05-19T07:00:00+00:00", "published_display": "19 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQcjZqdzdBcURDdWxCZUtoU1dTaHYtVUFRdlo1a3ZGZGY3a1dBX2x2UVE3Y1hoX1duLXhGU2p0UXU2eTctNng5eFJ5c1M0bHBNQ0VmZTFZanhYU21yTVo0UTQtVENveVV1aWdpc3luUlgza3AyUEI2OGx4aEhXc0pBTHpWUThSYXI1S3RTS21lQ21vWjd6MGY4ZDRwVWlEakc3SmFKN09aM0Rlb2pFT3BNNW1GTExnSElFb2NqR3JhX0J3MlptQy1mMk9IOTZtdS1HU25fLU9aOU9XZi1PRDlkZVI2cnhackHSAewBQVVfeXFMTlc2N3pIUkxDd1NtTlVRMEdac1JNSDF3cUNidkZrTElQREZaUTZjZmFHdUVWYW8wcDg1LThGbnlPb0VQUFI4ZXdjSXR6Ym5DREM1X2lyQUtYTzF3XzBBTGRGcEZQQ3FjLWxCQ0locVM2dGZJR1kxYmlBQXdsbFhfbFFISS1wSUkxQmp4U2d2Z3JHbXRPMUpnajBydTRmNnQzZmF5eEdzOVFRNUdDNVV0aDJQNERCaXN3ZGo1UUc1ZGkwOFYzcDgxS1ltZllDeTFxNFIxT3FyOUxLMFNrLUhtOFNFV0xMYkM5TlpWMzk?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Ocular Therapeutix (OCUL) Heavy Losses Challenge Bullish Growth Narratives In Q1 2026 Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocular Therapeutix\u2122 Reports First Quarter 2026 Financial Results and Business Highlights", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8AFBVV95cUxOUy1IZDEtRjBaZmZSNkxWSmlnRTliQmdCMVBNTk5lcU5BYUNaZjk4TFVGUElXenhieEVfZUZFOVhMdkQxaEhVMFZtdmVNc2FkSERjYjVsbzAxaXplUV9LMm10U015Q21KYUtkUTNrSEl2bTRHc1VLdDZNdUROUTJfUzdHdlR4dS1HbUlaUTdLbFY4WVk0RVhkZjUzS3Z2NGpuUkVzZi1lNFJ1VU9LVjVkLUF2bnJpUnBsdTFONEsxaWpBTk1mNmtVeFE0TFRwT2YxcjBuekFHUU5pQVQ5UDQzWTBza2k2TFpXSDF6T0ZUdnk?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Investors Are Reacting To Ocular Therapeutix (OCUL) Advancing AXPAXLI Toward NDA After Positive SOL-1 Trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxOYkdCY1NBdFg5S0pUZjVLQjNmR0QwWmE5NkhhbllITjVlalRkRVNvMnNGeUpaZXczVEN3dzl2OEVKZGRVanJIQ01BRnViT0dtcW5ybndjT19VTXdEVWtOaGI3bUtVaTZzYUtJTU5JbFJpdGhnTktDUTY3aDczcTVvVUdsaHlUam5aXzNEYlc0SHJ6YjR5YkpNSEkya2Roa0ljRjA4Y0tha3BCRzhLSXBSdQ?oc=5", "source_name": "Market source", "published_at": "2026-05-01T07:00:00+00:00", "published_display": "01 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Ocular Therapeutix Data Strengthens AXPAXLI Durability Case And FDA Ambitions", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Ocular Therapeutix (OCUL) Announces Additional Positive Data From the SOL-1 Phase 3 Superiority Trial of AXPAXLI", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPT3RUc1ZWLWtfQmpGQUJuUWkxcHhIMlY0OVhfdFFxQS13NzJkN2l4LUZYTmZBZUU5TTRTanZhRy1SdGxPaEo4eks0T3BoSFRUYzdGQktfUi1hWVhjLVVuOTZRTkUtMzlDajF0ZHpSXzVMQ0lzZFhzVlNMT09HendtR3RONGVPbGZIbUU3YjdVVHJvbUVmUDByc3hxZkxjWUxKanVFSjItRGNhQnRicFNHejJDUQ?oc=5", "source_name": "Market source", "published_at": "2026-04-19T07:00:00+00:00", "published_display": "19 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Time To Reconsider Ocular Therapeutix (OCUL) After Its Recent Share Price Swings?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-16T07:00:00+00:00", "published_display": "16 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Ocular Therapeutix (OCUL) Quietly Recasting Its Retinal Strategy Around Axpaxli\u2019s Phase 3 Design Choices?", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxQQmdGOXFLckszYWtPU0l4dWVYbW1TemZVcFhPNTYxa3htampoejFiUDJnRkx5cUFFeUhTcGdwNWc1SEVTMVItdVM0bU1sVXpxaWRjSDhtc2tkemZ1dzlZT2Z5X1cxTktJR2xsd2UwVGs1cWowRWpOSTN3MU9iTGRtNm0wbGVtZHE5NDIyV0ZxNGRpaENFYVJUTllmZ3UwRmVSYUs4WHZBajBHd0hKa1Bz?oc=5", "source_name": "Market source", "published_at": "2026-04-13T07:00:00+00:00", "published_display": "13 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocular Therapeutix (OCUL) Soars 10.4% Ahead of Business Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxNRHRLSjl4S25fakV6Y3NJMERoaXVBMnlCbFZ2MWNsVFBCUWNkLU9oalZuai1Nc2x3NmZDWmlvSUNRc3Z4YmdubmozWm03V21oM3lidy1NTFVzQzlPXzNtSFlBY2t2Ym1lRjVtc0RPNUQ2bmd4QjRwcHRkSmFpSWJsYkFBLVFYQWNjOGF3U080UklwcjFiWTJKOUhhUTludw?oc=5", "source_name": "Market source", "published_at": "2026-04-09T07:00:00+00:00", "published_display": "09 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here is Why Ocular Therapeutix (OCUL) is Highly Favored by Hedge Funds", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxQQ1Q3NlJWNS0xWW53MHBreU5HR285MHgwblpldWI0Y2phSmk0YkwtZUZ2SWV4QWd1Rlg1YjNZcFI2dXlPTjdGZTh6aVM2VEFMbzRMck5sY3h0c0JOcDlPWEhKdG9fTHFRNnJxQkRfbXBadnR4ekk1WHVhN25mQVZhUkppTElHa3lySFdJcldkd09kNkkxVDhMTEJUUU5td3UzQm94dHln?oc=5", "source_name": "Market source", "published_at": "2026-04-01T07:00:00+00:00", "published_display": "01 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Ocular Therapeutix Gets Black Eye, But I See Stock Rising on New Drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxPOHBHNVg3RXY5NGtUdzFnZ1ZIUVJyOTNJN2d5NzhrSkNodjVxVl9nT094ZzBMMHN4czFIR2wzTjdRSTdKQmpkenUydkh2N0FyVlJkWlhJYkxMYktnWFg4TVNlTHBpS0thQmhJemJUb2xiOVJhR3M4ZkF5VVhpdDM4cFlUMzZ2SlZaMmR6aUF2ODVLc2ZkaGxjZEgzMmF2RG1LMTJtU0J1S19SZw?oc=5", "source_name": "TheStreet Pro", "published_at": "2026-03-13T07:00:00+00:00", "published_display": "13 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocular Therapeutix, Inc. (OCUL): A Bull Case Theory", "summary": "", "url": "https://news.google.com/rss/articles/CBMigwFBVV95cUxQNG5sNHFUd1VfelhDREpZU0ZvVHlfcEVpMTFMek13OXFSaHd2SUtwdkJxa0M2X25vQnV4ZkpGQi0tZDlET2hxUWZJY0U2VGd2WEZ0bW9DdnFRV1V5aERfQ2dTZnZPczh4YmlodUJ2SVBrNHpLZE4wcjh6TUFucTlCZzk1SQ?oc=5", "source_name": "Finviz", "published_at": "2026-02-28T08:00:00+00:00", "published_display": "28 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Ocular Therapeutix (OCUL) Valuation After Recent Share Price Swings And AXPAXLI Expectations", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxQck1Gbm4zcXRvZk9hcnQ2OGJRNXIxdUxhUU56YWw2QjlSakhTRkJWVUxNUkFVTWdVUnVoOEJmOWN4eWxLcUJ4WFpaSE44S3o0Z0puY2JiSWFBTHRvSWZFd3hjT29GR3RYU0ZJMTJvV2lib2dUMVBmSlFObndNVXRWSXRnTFJJZDNnNXNKNW1YRVdLRGs?oc=5", "source_name": "Market source", "published_at": "2026-02-28T08:00:00+00:00", "published_display": "28 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocular Therapeutix (OCUL) Stock Trades Down, Here Is Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxPZ1ZWZlZqUVZQd2xZejVBZzNYekhRaTQwb0FYV2FISHVqbnVaTVUzMWZpX085OXRNRDJxWG5KMGlWbXNQeTJIazJXN180amNvLXZMTUxwc2EtcElzamFaR2hTLUdCMTVINDNManRSZ2thczIxTHdtTnlacGdTemdRUDBESm1qZjBiR3c?oc=5", "source_name": "Market source", "published_at": "2026-02-27T08:00:00+00:00", "published_display": "27 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocular Therapeutix CSO Heier sells $25k in stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxPSll6RmNwRG1tVkdjcEt3bzljc1htMV9wWTE4UE5DdzZSNEQ3T0Nxa21JekcySm1PTEg3Z0pBLUtpUllIbWZsN0o1eEVpMURSWm9pSGNscVF2bXdjVmhyb3dPNDVxTU04NVdja094dExqU2dRVWFwcjJpbUowVXdBVmZxNlduRjhCU1QyanhXd3lqQXF0dkF1ZC1FZWRuelZzVm9JMGY3WVVsUFppUk1FZzZn?oc=5", "source_name": "Investing.com", "published_at": "2026-02-25T08:00:00+00:00", "published_display": "25 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Reassessing Ocular Therapeutix (OCUL) After Sharp Pullback And Conflicting Valuation Signals", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxQRDJOUV9LMHBzUnNTcnF5a3pJeEc3cXl3RG00OHI0d3JoRnJ2UTZHdk5PTjBsejNRbmItQ2tpdTdBT0NGTFVRT0dSZlpyMFhSNTQ4cEVlZE0tY3hWckFJVlp2c2Q1RGJsb2RHcjVhenIzZE9IYXBuZHplZVpOME13UWQybENvS0t1N0JYRUNJXzM?oc=5", "source_name": "Market source", "published_at": "2026-02-22T08:00:00+00:00", "published_display": "22 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Citizens reiterates Ocular Therapeutix stock rating on Dextenza sales", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxNN1hWcmMtLUFhN1pWNmpCSjVfNHRvdlBiN0Zfa2JoeU1YTXJxdFB2eml3NlgyVkphREVEd1pJZE5yLUFVNkcyeXo0azRXc2FnQWZQTncxME5WWFJSWVQyLWh5bXU0Mms5RXFDazU5bmtpeXVFdFMxM0xQRGhwREM4akFVNVlvMkp0RVlQRmZhc3ZNWkdKR1lwa2FUZ2RjRTVQSHVaYmIyMWtYX0hfNGgxb1EtaUpNVjhVTl9SaDBzUGs4VEdwZUlKbQ?oc=5", "source_name": "Investing.com", "published_at": "2026-07-17T10:42:46+00:00", "published_display": "17 Jul 2026 10:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nasdaq, S&P 500 Futures Lower As AI Disruption Fears Linger: Why AAPL, ZIM, OCUL, NCLH Are On Traders' Radar Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxNMWlVUlMxNmxZNFZvb3J0cWpqa3l1aW1hUDZnT2Fwc25hQ3poM29TV1BOdmFTSVVaMWtuR2ZPZGJRZjVfS0xlWVE4RjFwY3U4UnMwTmxEY082b2xlanJabDVuLWkxU1o3SDFUNVhxcmhjV1o1RThPdVFBckpBV2NRbVJsMFhTTHllTVZ1UTZscmEwenZNUlhZME1IUUE4a2lTX3NMQTZtN1Z1eXNWTm9xOWVjQ3h5UWR6d0NJcHh3Y0UwUQ?oc=5", "source_name": "Stocktwits", "published_at": "2026-07-16T14:06:06+00:00", "published_display": "16 Jul 2026 14:06", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocular Therapeutix Inc (OCUL) Institutional Confidence", "summary": "", "url": "https://news.google.com/rss/articles/CBMicEFVX3lxTE5FY1JkUFVFNEdRZUgySVRVeWUwU2lNbXhLcXJaNjRTTnhtVDFIc0Rxa3loQ1JhYkQ3Ny0yb3VGUVlpM254RHFzLWVQMEphNC1RN2YzUjZoSGVsTzlZbGNOZGt0RzRXNmZibVF3X19ubGg?oc=5", "source_name": "TradingKey", "published_at": "2026-07-14T07:00:00+00:00", "published_display": "14 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(OCUL) Price Dynamics and Execution-Aware Positioning", "summary": "This article from Stock Traders Daily provides a detailed AI-driven analysis of Ocular Therapeutix Inc. (NASDAQ: OCUL), highlighting strong near and mid-term sentiment potentially shifting to a weak long-term outlook. It outlines specific institutional trading strategies, includi", "url": "https://news.stocktradersdaily.com/news_release/22/OCUL_Price_Dynamics_and_Execution-Aware_Positioning_071226014602_1783835162.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-12T01:41:34", "published_display": "12 Jul 2026 01:41", "sentiment": "negative", "sentiment_pct": 38, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocular Therapeutix\u2122 Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)", "summary": "Ocular Therapeutix, Inc. announced inducement grants to eleven new non-executive employees, consisting of stock options and restricted stock units. These awards, totaling 34,700 shares for options and 11,375 for RSUs, were made under Ocular\u2019s 2019 Inducement Stock Incentive Plan ", "url": "https://www.globenewswire.com/news-release/2026/07/09/3325203/0/en/ocular-therapeutix-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html", "source_name": "GlobeNewswire", "published_at": "2026-07-10T07:11:15", "published_display": "10 Jul 2026 07:11", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Does Ocular Therapeutix (OCUL) Joining Russell Value Indexes Quietly Recast Its Long\u2011Term Investor Base?", "summary": "Ocular Therapeutix (OCUL) was recently added to several Russell Value indexes, which could increase its visibility to institutional investors and improve trading volumes. While this inclusion may boost short-term liquidity, the company's long-term investment narrative remains dep", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ocul/ocular-therapeutix/news/does-ocular-therapeutix-ocul-joining-russell-value-indexes-q", "source_name": "Simply Wall Street", "published_at": "2026-07-10T05:09:42", "published_display": "10 Jul 2026 05:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocular Therapeutix (OCUL) Joins Russell Value Indexes, Is The Stock Now Too Pricey?", "summary": "Ocular Therapeutix (OCUL), recently added to Russell indexes, has seen a sharp rebound in its stock price, but remains down year-to-date. Despite being considered \"undervalued\" with a fair value of $26 based on the potential of its drug AXPAXLI, its current price-to-sales ratio i", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ocul/ocular-therapeutix/news/ocular-therapeutix-ocul-joins-russell-value-indexes-is-the-s/amp", "source_name": "Simply Wall Street", "published_at": "2026-07-08T12:09:50", "published_display": "08 Jul 2026 12:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocular Therapeutix options trading jumps to 9,894 contracts", "summary": "Trading in options for Ocular Therapeutix Inc. (NASDAQ:OCUL) surged to 9,894 contracts by 10:51 a.m. New York time, with call volume notably higher than put volume. Specifically, the July 17, 2026 $9 call option accounted for 9,807 contracts. Despite the increased options activit", "url": "https://www.investing.com/news/stock-market-news/ocular-therapeutix-options-trading-jumps-to-9894-contracts-93CH-4776966", "source_name": "Investing.com", "published_at": "2026-07-06T15:11:43", "published_display": "06 Jul 2026 15:11", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocular Therapeutix Inc Actuals & Estimates (NASDAQ:OCUL)", "summary": "Ocular Therapeutix Inc. (NASDAQ: OCUL) stock is currently priced at $10.16, showing a 6.94% increase in the past 24 hours. Analysts project a price target range of $18.00 to $34.00, indicating potential growth. The company reported earnings per share of -$0.40 last quarter, missi", "url": "https://www.tradingview.com/symbols/NASDAQ-OCUL/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-07-04T19:09:50", "published_display": "04 Jul 2026 19:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Ocular Therapeutix, Inc. \u2013 NASDAQ:OCUL", "summary": "This article provides the stock ticker (OCUL) and company name (Ocular Therapeutix, Inc.) along with a financial metric: Price to Earnings Forward. It indicates that the market is currently closed and no trades have occurred for the stock.", "url": "https://www.tradingview.com/symbols/NASDAQ-OCUL/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-04T08:11:07", "published_display": "04 Jul 2026 08:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Ocular Therapeutix, Inc. \u2013 NASDAQ:OCUL", "summary": "This article focuses on the price-to-sales forward metric for Ocular Therapeutix, Inc. (NASDAQ: OCUL). The content, provided by TradingView, lists the company's financial overview and other market data points like financials, news, and technicals. It indicates that the market for", "url": "https://www.tradingview.com/symbols/NASDAQ-OCUL/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-03T15:10:09", "published_display": "03 Jul 2026 15:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OCUL - Ocular Therapeutix Inc Revenue Breakdown", "summary": "This article provides a comprehensive financial overview of Ocular Therapeutix Inc. (OCUL), detailing its revenue breakdown, market performance, key financial ratios, and analyst recommendations. It includes data on market capitalization, income, sales, earnings per share, inside", "url": "https://finviz.com/stock?t=OCUL&ty=rv&=scroll", "source_name": "Finviz", "published_at": "2026-07-02T12:39:34", "published_display": "02 Jul 2026 12:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocular Therapeutix to present new retinal disease data at July 2026 scientific and investor conferences", "summary": "Ocular Therapeutix announced its plans to present new data on its investigational retinal drug AXPAXLI and real-world anti-VEGF treatment outcomes at various scientific and investor conferences in July 2026. These events include the OIS Retina Innovation Summit and the American S", "url": "https://pluang.com/en/news-feed/ocular-therapeutix-ikut-konferensi-ilmiah-dan-investor-juli-2026", "source_name": "Pluang", "published_at": "2026-07-01T12:11:38", "published_display": "01 Jul 2026 12:11", "sentiment": "positive", "sentiment_pct": 67, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocular Therapeutix\u2122 to Participate in July Scientific and Investor Conferences", "summary": "Ocular Therapeutix, Inc. (NASDAQ: OCUL) announced its participation in multiple scientific and investor conferences in July 2026. These events include the 9th Annual OIS Retina Innovation Summit, the American Society of Retina Specialists 44th Annual Meeting, and the HC Wainwrigh", "url": "https://www.globenewswire.com/news-release/2026/07/01/3320488/0/en/ocular-therapeutix-to-participate-in-july-scientific-and-investor-conferences.html", "source_name": "GlobeNewswire", "published_at": "2026-07-01T11:11:38", "published_display": "01 Jul 2026 11:11", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocular Therapeutix will present SOL-1 data at July retina meetings", "summary": "Ocular Therapeutix (NASDAQ: OCUL) announced its participation in multiple scientific and investor conferences in July 2026. The company will present Phase 3 SOL-1 trial results for OTX-TKI in neovascular age-related macular degeneration (nAMD) at the ASRS 44th Annual Meeting and ", "url": "https://www.stocktitan.net/news/OCUL/ocular-therapeutix-tm-to-participate-in-july-scientific-and-investor-llrsd185hy8g.html", "source_name": "Stock Titan", "published_at": "2026-07-01T11:11:38", "published_display": "01 Jul 2026 11:11", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Does Broad Russell Value Index Inclusion Reshape the Bull Case for Ocular Therapeutix (OCUL)?", "summary": "Ocular Therapeutix (OCUL) was recently added to several Russell value indices, which could increase its visibility among institutional investors and improve liquidity. While this inclusion may reshape market perception of Ocular Therapeutix's risk profile, the company's investmen", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ocul/ocular-therapeutix/news/does-broad-russell-value-index-inclusion-reshape-the-bull-ca", "source_name": "Simply Wall Street", "published_at": "2026-07-01T11:11:38", "published_display": "01 Jul 2026 11:11", "sentiment": "positive", "sentiment_pct": 67, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocular Therapeutix (OCUL) Could Be 62% Below Fair Value After Axpaxli FDA Feedback", "summary": "Ocular Therapeutix (OCUL) is in the spotlight due to positive FDA feedback on its drug Axpaxli, intended for wet age-related macular degeneration. Despite a recent share price surge, the company's year-to-date performance is down, though its three-year shareholder return remains ", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ocul/ocular-therapeutix/news/ocular-therapeutix-ocul-could-be-62-below-fair-value-after-a", "source_name": "Simply Wall Street", "published_at": "2026-06-29T03:39:43", "published_display": "29 Jun 2026 03:39", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OCUL Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides an in-depth forecast for Ocular Therapeutix, Inc. (OCUL) stock, including current price, analyst price targets, and historical performance. It details financial metrics such as EPS, revenue, net income, and EBITDA, along with frequently asked questions about", "url": "https://www.tradingview.com/symbols/NASDAQ-OCUL/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-27T00:09:08", "published_display": "27 Jun 2026 00:09", "sentiment": "positive", "sentiment_pct": 60, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocular Therapeutix Inc Actuals & Estimates (BX:0OT)", "summary": "This article provides an overview of Ocular Therapeutix Inc (BX:0OT) stock, including its current price, market capitalization, and historical performance. It also details financial actuals and estimates, analyst forecasts for future prices, and information on earnings reports, r", "url": "https://www.tradingview.com/symbols/BX-0OT/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T15:14:24", "published_display": "26 Jun 2026 15:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocular Therapeutix Inc Actuals & Estimates (FWB:0OT)", "summary": "This article provides financial actuals and estimates for Ocular Therapeutix Inc (FWB:0OT), including analyst opinions on future prices, historical stock performance, and past earnings reports. It details the company's revenue, net income, EBITDA, and employee count, confirming t", "url": "https://www.tradingview.com/symbols/FWB-0OT/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T11:09:08", "published_display": "26 Jun 2026 11:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OCUL Maintained by Chardan Capital -- Price Target Raised to $23", "summary": "Chardan Capital has reiterated its \"Buy\" rating for Ocular Therapeutix (OCUL) and raised its price target from $21.00 to $23.00, signaling optimism about the company's future. Despite this positive analyst sentiment, GuruFocus indicates that OCUL is significantly overvalued by 12", "url": "https://www.gurufocus.com/news/8931844/ocul-maintained-by-chardan-capital-price-target-raised-to-2300", "source_name": "GuruFocus", "published_at": "2026-06-25T14:39:58", "published_display": "25 Jun 2026 14:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chardan Raises Price Target on Ocular Therapeutix to $23 From $21, Keeps Buy Rating", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/chardan-raises-price-target-ocular-111221755.html", "source_name": "MT Newswires", "published_at": "2026-06-25T11:12:21+00:00", "published_display": "25 Jun 2026 11:12", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Ocular Therapeuticx, Inc. (OCUL) Stock Positioned for Growth After Positive FDA Feedback on Axpaxli?", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxQQWZ6c1hZdDRIa3FaTXUwa3I5VGp4a0FIekRTTUNiZnNQYllkc3VJXzVWSkJFMDI3Wk00WTJaLW5kWW54Wkk5SERaNk1fYk5iamliZV84VlR5dnNFNF9Oc3djSHZLMEtadUhkRlRzM3RTd2lOUURsM1Fnd3ZoTW1nelE3Y0VGdEhrOG4zcTZ5RG1OdmE5T0dnZGtfMA?oc=5", "source_name": "Market source", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "5 Best Healthcare Stocks to Buy According to Wall Street Analysts", "summary": "Ocular Therapeutix, Inc. (NASDAQ: OCUL) is highlighted as one of the best healthcare stocks, with H.C. Wainwright increasing its price target to $25 based on positive feedback from a Type C meeting with the FDA for AXPAXLI. The company plans to submit a New Drug Application for A", "url": "https://www.insidermonkey.com/blog/5-best-healthcare-stocks-to-buy-according-to-wall-street-analysts-1788076/5/", "source_name": "Insider Monkey", "published_at": "2026-06-24T19:39:00", "published_display": "24 Jun 2026 19:39", "sentiment": "positive", "sentiment_pct": 74, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocular Therapeutix (OCUL): Buy, Sell, or Hold Post Q1 Earnings?", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxQQzJaS050bXRKQ1FZdVpodlRyS0pTcG1iU0JLX2Y1dUlQSjlPUnhqZkVOYkt2YWlEQ0FsanhoZzA0Z2gtN3duWFBZVldLVThncHZyNHYtZTd6VVFPOHdwbXZZelRPM0FseFEzVUR4TmJEUHIxbXB6dm8wc0V3elIzOUZ1eU0tVFp5WDQ5SWVmRUNPaXc5dklHdEVmTlBrUQ?oc=5", "source_name": "Market source", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)", "summary": "Ocular Therapeutix announced inducement grants under Nasdaq Listing Rule 5635(c)(4). These grants are typically given to new employees as an incentive to join the company. This action reflects the company's efforts to attract and retain talent in line with Nasdaq's regulatory fra", "url": "https://www.moomoo.com/news/post/71847001/ocular-therapeutix-reports-inducement-grants-under-nasdaq-listing-rule-5635", "source_name": "Moomoo", "published_at": "2026-06-23T13:09:10", "published_display": "23 Jun 2026 13:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright raises Ocular Therapeutix price target to $25 on FDA pathway clarity", "summary": "H.C. Wainwright has increased its price target for Ocular Therapeutix (NASDAQ:OCUL) to $25 from $21, maintaining a Buy rating. This adjustment follows Ocular Therapeutix's Investor Day, where the company provided clarity on its FDA pathway for AXPAXLI, including aligning with the", "url": "https://ng.investing.com/news/stock-market-news/hc-wainwright-raises-ocular-therapeutix-price-target-to-25-on-fda-pathway-clarity-93CH-2567443", "source_name": "Investing.com Nigeria", "published_at": "2026-06-23T00:39:56", "published_display": "23 Jun 2026 00:39", "sentiment": "positive", "sentiment_pct": 75, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocular Therapeutix grants new SVP equity awards tied to hiring", "summary": "Ocular Therapeutix (NASDAQ: OCUL) has awarded inducement equity grants to Kelley Allison, its new SVP of Market Access and Health Policy, under its 2019 Inducement Stock Incentive Plan. These grants include options for 85,000 shares at an exercise price of $8.99 and 28,000 Restri", "url": "https://www.stocktitan.net/news/OCUL/ocular-therapeutix-tm-reports-inducement-grants-under-nasdaq-listing-4yx69oxb2vn0.html", "source_name": "Stock Titan", "published_at": "2026-06-22T20:11:11", "published_display": "22 Jun 2026 20:11", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stocks making big moves yesterday: Nubank, Ocular Therapeutix, Mondelez, ResMed, and Sonos", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/stocks-making-big-moves-yesterday-151728482.html", "source_name": "StockStory", "published_at": "2026-06-18T15:17:28+00:00", "published_display": "18 Jun 2026 15:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocular Therapeutix Says Axpaxli New Drug Application Submission to US FDA Planned for Q4", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/ocular-therapeutix-says-axpaxli-drug-141652961.html", "source_name": "MT Newswires", "published_at": "2026-06-17T14:16:52+00:00", "published_display": "17 Jun 2026 14:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Ocular Therapeutix (OCUL) Stock Is Up Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxQV3hTbWNKX0lKUXQyYzZDemtKY2pDVUtIQkphTy1uT3hlNVJRWEMwUDY1ZHpvNDZMV0UxZWxSckxJMExKb2t1dGdmUWlnMHpOY09wdEJpQ2pMNmdBdlJzTVhNR3RkeW1PRDFPU3ZzckVmaHpzd1Z3Rjh4MVZmdmdsODVVM3NqQkhEWG5WdnVJMzNIWjF4ZmhEZ1NB?oc=5", "source_name": "Market source", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocular Therapeutix maps AXPAXLI filing for wet AMD after FDA alignment", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxQSEVVVm5IS1ktMUltQnVCVzkzaGxvWnlKbkg0SjB2bjZCUFRlV0ZMZ1RxNEtvQmNfYjNMel9vYV9iMmtnSzA0MG1RRzFzaEJSTXU5b0RUWXpBa3dkMGVjcFJ4cWZVdXpsVkRRUkJJWVItRXNNTVdiTkdlVFZjYzN1SE5kSGVXSFBNWWVmb2NNX0NnOGVmMVZLaTEwYTVTbEVaRUR4MXU3b0pUM1FYOG1lYWlZWm96Z1Q2dWNfMWVaQ0Y?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocular Therapeutix plans wet AMD drug filing in Q4 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxObHBoS3B1OE9POUpsYW1nd2dDUXV0RjRYUDdzSGVyUFgyZmk0RmcxOHBnTnUwXzRvNUZjRmJxVXVjS0pjaFYtVVpfMjBMS3NNc1VqM1FfdGRZMUJrbkVLaEJvSXY4TjZ3emVjdk1Qem0tODJOOHNlWTRYSUZRdzJ3eFpkeS1VNmd3RVVILWg3bHJtajIzUkpra3p4UTdmX25uVWxMaS1lUFMtS3dpemxhNnFn?oc=5", "source_name": "Investing.com", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocular Therapeutix vs. Prime Medicine: Which Healthcare Stock Is a Better Buy in 2026?", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxQZllJdWRvZFgyZmg3WTR4T2I0MG16eEtUOXk1RzNTRGhpLWhLUnFMVnRZN1JrT2JtUDhJRHIxT2pGdVR6UDdNcUtIS3B3YUdGUFFNbWlqWGJHbHRXajE5N3VXdnRzekdCeFM3S2tpbVF2bjQ4SUlkTG5OMUJpWkN1VWkwT2ZRWF9JdFljQi02S2J1UHZSLXRPWUk2SDRqMEJYUUxONWJHMFBGZnppTm9mTlQ0eko0blhKVUFIR2N4eEI3dDZTQTN6LUoyczNNQmJfeXc?oc=5", "source_name": "The Motley Fool", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocular Therapeutix vs. Prime Medicine: A 2026 Analysis of Medical Innovation Stocks - News and Statistics", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxNWmVXNFFqeG1CSVJyMkJhYmV4NHV6Q3dGX2I2RTJGdWdYUkE5RlpiQUxZTEliemVKU3A4QXFLbjZxa1NmbVFKbzN3akNQS0pZcC1yeXUxVFNRdVFHVEFBcmQ1YkdLRVFubXJUQndSYXNNUll0elhlRW1uUkxXLU0tdHlTVmllZ0xZTzNTZmRLZ3lRZjlSVEFVX01uYTljVDBPaHJRWDllR0RnbDdCdzRHckxfUjFqZVhWMFE?oc=5", "source_name": "IndexBox", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What This Fund\u2019s $14 Million Ocular Therapeutix Exit Could Signal for Investors", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxQbXNhdk1DTkMyQjJYWFdPVXZWNmxMVlZWaFBVajNDNWdZTkNBeDNRaVpyckZEcXI5RXo0em9LQUJTSzN4VUtnZFFUSW5fYnBYTmJYeGozZ2x6aHFITWNhRmhpYlFkS0ppaEZJUm9VbEVhZ2F4TEVicTlOdE02YmE2NlhjOG1DYUNUU0p6OU1XZnVmcmcycm5zQ05aMk1pTnBI?oc=5", "source_name": "Market source", "published_at": "2026-05-19T07:00:00+00:00", "published_display": "19 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocular Therapeutix (OCUL) Heavy Losses Challenge Bullish Growth Narratives In Q1 2026 Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocular Therapeutix\u2122 Reports First Quarter 2026 Financial Results and Business Highlights", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8AFBVV95cUxOUy1IZDEtRjBaZmZSNkxWSmlnRTliQmdCMVBNTk5lcU5BYUNaZjk4TFVGUElXenhieEVfZUZFOVhMdkQxaEhVMFZtdmVNc2FkSERjYjVsbzAxaXplUV9LMm10U015Q21KYUtkUTNrSEl2bTRHc1VLdDZNdUROUTJfUzdHdlR4dS1HbUlaUTdLbFY4WVk0RVhkZjUzS3Z2NGpuUkVzZi1lNFJ1VU9LVjVkLUF2bnJpUnBsdTFONEsxaWpBTk1mNmtVeFE0TFRwT2YxcjBuekFHUU5pQVQ5UDQzWTBza2k2TFpXSDF6T0ZUdnk?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Investors Are Reacting To Ocular Therapeutix (OCUL) Advancing AXPAXLI Toward NDA After Positive SOL-1 Trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxOYkdCY1NBdFg5S0pUZjVLQjNmR0QwWmE5NkhhbllITjVlalRkRVNvMnNGeUpaZXczVEN3dzl2OEVKZGRVanJIQ01BRnViT0dtcW5ybndjT19VTXdEVWtOaGI3bUtVaTZzYUtJTU5JbFJpdGhnTktDUTY3aDczcTVvVUdsaHlUam5aXzNEYlc0SHJ6YjR5YkpNSEkya2Roa0ljRjA4Y0tha3BCRzhLSXBSdQ?oc=5", "source_name": "Market source", "published_at": "2026-05-01T07:00:00+00:00", "published_display": "01 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocular Therapeutix Data Strengthens AXPAXLI Durability Case And FDA Ambitions", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocular Therapeutix (OCUL) Announces Additional Positive Data From the SOL-1 Phase 3 Superiority Trial of AXPAXLI", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPT3RUc1ZWLWtfQmpGQUJuUWkxcHhIMlY0OVhfdFFxQS13NzJkN2l4LUZYTmZBZUU5TTRTanZhRy1SdGxPaEo4eks0T3BoSFRUYzdGQktfUi1hWVhjLVVuOTZRTkUtMzlDajF0ZHpSXzVMQ0lzZFhzVlNMT09HendtR3RONGVPbGZIbUU3YjdVVHJvbUVmUDByc3hxZkxjWUxKanVFSjItRGNhQnRicFNHejJDUQ?oc=5", "source_name": "Market source", "published_at": "2026-04-19T07:00:00+00:00", "published_display": "19 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Time To Reconsider Ocular Therapeutix (OCUL) After Its Recent Share Price Swings?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-16T07:00:00+00:00", "published_display": "16 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Ocular Therapeutix (OCUL) Quietly Recasting Its Retinal Strategy Around Axpaxli\u2019s Phase 3 Design Choices?", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxQQmdGOXFLckszYWtPU0l4dWVYbW1TemZVcFhPNTYxa3htampoejFiUDJnRkx5cUFFeUhTcGdwNWc1SEVTMVItdVM0bU1sVXpxaWRjSDhtc2tkemZ1dzlZT2Z5X1cxTktJR2xsd2UwVGs1cWowRWpOSTN3MU9iTGRtNm0wbGVtZHE5NDIyV0ZxNGRpaENFYVJUTllmZ3UwRmVSYUs4WHZBajBHd0hKa1Bz?oc=5", "source_name": "Market source", "published_at": "2026-04-13T07:00:00+00:00", "published_display": "13 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocular Therapeutix (OCUL) Soars 10.4% Ahead of Business Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxNRHRLSjl4S25fakV6Y3NJMERoaXVBMnlCbFZ2MWNsVFBCUWNkLU9oalZuai1Nc2x3NmZDWmlvSUNRc3Z4YmdubmozWm03V21oM3lidy1NTFVzQzlPXzNtSFlBY2t2Ym1lRjVtc0RPNUQ2bmd4QjRwcHRkSmFpSWJsYkFBLVFYQWNjOGF3U080UklwcjFiWTJKOUhhUTludw?oc=5", "source_name": "Market source", "published_at": "2026-04-09T07:00:00+00:00", "published_display": "09 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here is Why Ocular Therapeutix (OCUL) is Highly Favored by Hedge Funds", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxQQ1Q3NlJWNS0xWW53MHBreU5HR285MHgwblpldWI0Y2phSmk0YkwtZUZ2SWV4QWd1Rlg1YjNZcFI2dXlPTjdGZTh6aVM2VEFMbzRMck5sY3h0c0JOcDlPWEhKdG9fTHFRNnJxQkRfbXBadnR4ekk1WHVhN25mQVZhUkppTElHa3lySFdJcldkd09kNkkxVDhMTEJUUU5td3UzQm94dHln?oc=5", "source_name": "Market source", "published_at": "2026-04-01T07:00:00+00:00", "published_display": "01 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocular Therapeutix Gets Black Eye, But I See Stock Rising on New Drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxPOHBHNVg3RXY5NGtUdzFnZ1ZIUVJyOTNJN2d5NzhrSkNodjVxVl9nT094ZzBMMHN4czFIR2wzTjdRSTdKQmpkenUydkh2N0FyVlJkWlhJYkxMYktnWFg4TVNlTHBpS0thQmhJemJUb2xiOVJhR3M4ZkF5VVhpdDM4cFlUMzZ2SlZaMmR6aUF2ODVLc2ZkaGxjZEgzMmF2RG1LMTJtU0J1S19SZw?oc=5", "source_name": "TheStreet Pro", "published_at": "2026-03-13T07:00:00+00:00", "published_display": "13 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocular Therapeutix, Inc. (OCUL): A Bull Case Theory", "summary": "", "url": "https://news.google.com/rss/articles/CBMigwFBVV95cUxQNG5sNHFUd1VfelhDREpZU0ZvVHlfcEVpMTFMek13OXFSaHd2SUtwdkJxa0M2X25vQnV4ZkpGQi0tZDlET2hxUWZJY0U2VGd2WEZ0bW9DdnFRV1V5aERfQ2dTZnZPczh4YmlodUJ2SVBrNHpLZE4wcjh6TUFucTlCZzk1SQ?oc=5", "source_name": "Finviz", "published_at": "2026-02-28T08:00:00+00:00", "published_display": "28 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Ocular Therapeutix (OCUL) Valuation After Recent Share Price Swings And AXPAXLI Expectations", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxQck1Gbm4zcXRvZk9hcnQ2OGJRNXIxdUxhUU56YWw2QjlSakhTRkJWVUxNUkFVTWdVUnVoOEJmOWN4eWxLcUJ4WFpaSE44S3o0Z0puY2JiSWFBTHRvSWZFd3hjT29GR3RYU0ZJMTJvV2lib2dUMVBmSlFObndNVXRWSXRnTFJJZDNnNXNKNW1YRVdLRGs?oc=5", "source_name": "Market source", "published_at": "2026-02-28T08:00:00+00:00", "published_display": "28 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocular Therapeutix (OCUL) Stock Trades Down, Here Is Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxPZ1ZWZlZqUVZQd2xZejVBZzNYekhRaTQwb0FYV2FISHVqbnVaTVUzMWZpX085OXRNRDJxWG5KMGlWbXNQeTJIazJXN180amNvLXZMTUxwc2EtcElzamFaR2hTLUdCMTVINDNManRSZ2thczIxTHdtTnlacGdTemdRUDBESm1qZjBiR3c?oc=5", "source_name": "Market source", "published_at": "2026-02-27T08:00:00+00:00", "published_display": "27 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocular Therapeutix CSO Heier sells $25k in stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxPSll6RmNwRG1tVkdjcEt3bzljc1htMV9wWTE4UE5DdzZSNEQ3T0Nxa21JekcySm1PTEg3Z0pBLUtpUllIbWZsN0o1eEVpMURSWm9pSGNscVF2bXdjVmhyb3dPNDVxTU04NVdja094dExqU2dRVWFwcjJpbUowVXdBVmZxNlduRjhCU1QyanhXd3lqQXF0dkF1ZC1FZWRuelZzVm9JMGY3WVVsUFppUk1FZzZn?oc=5", "source_name": "Investing.com", "published_at": "2026-02-25T08:00:00+00:00", "published_display": "25 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Reassessing Ocular Therapeutix (OCUL) After Sharp Pullback And Conflicting Valuation Signals", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxQRDJOUV9LMHBzUnNTcnF5a3pJeEc3cXl3RG00OHI0d3JoRnJ2UTZHdk5PTjBsejNRbmItQ2tpdTdBT0NGTFVRT0dSZlpyMFhSNTQ4cEVlZE0tY3hWckFJVlp2c2Q1RGJsb2RHcjVhenIzZE9IYXBuZHplZVpOME13UWQybENvS0t1N0JYRUNJXzM?oc=5", "source_name": "Market source", "published_at": "2026-02-22T08:00:00+00:00", "published_display": "22 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 99, "total_relevant": 63, "sentiment_summary": {"positive": 17, "negative": 4, "neutral": 42, "score": 54, "total": 63, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 80, "events": [{"event": "general", "label": "Market update", "weight": 18.7, "count": 34}, {"event": "earnings", "label": "Earnings", "weight": 9.21, "count": 19}, {"event": "analyst", "label": "Analyst action", "weight": 2.75, "count": 5}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.1, "count": 2}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.1, "count": 2}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}], "positive_events": 17, "negative_events": 4}, "market_context": {"has_market_context": true, "latest_close": 10.2, "latest_week": "2026-07-10", "one_week_move": 5.8, "four_week_move": 14.1, "twelve_week_move": 3.9, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.923908, "market_dynamics_buy_signal": false, "relative_strength": -18.634809, "fair_value_gap": 25.4, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 47.1562, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+5.8% over one week, +14.1% over four weeks, trend inactive, and materially above fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 63, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 18}, {"label": "TradingView", "count": 7}, {"label": "simplywall.st", "count": 5}, {"label": "Investing.com", "count": 4}, {"label": "Simply Wall Street", "count": 4}, {"label": "GlobeNewswire", "count": 3}, {"label": "Stock Titan", "count": 3}, {"label": "Finviz", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 54}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 34}, {"label": "Earnings", "count": 19}, {"label": "Analyst action", "count": 5}, {"label": "Balance sheet", "count": 2}, {"label": "Regulatory and legal", "count": 2}, {"label": "Guidance", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "54/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "80/100 classification confidence."}, {"label": "Company focus", "value": "54", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+5.8% over one week, +14.1% over four weeks, trend inactive, and materially above fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Citizens reiterates Ocular Therapeutix stock rating on Dextenza sales"}], "updated_at": "2026-07-17T13:07:36.841179+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}